J. C. Netelenbos

发表

Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW).

A. LaCroix, C. Cooper, S. Boonen, 2011, Bone.

Obesity is not protective against fracture in postmenopausal women: GLOW.

Julie Flahive, Kenneth G Saag, Steven Boonen, 2011, The American journal of medicine.

Reproducibility of bone mineral density measurement in daily practice

B. Dijkmans, H. Adèr, J. C. Netelenbos, 2004, Annals of the rheumatic diseases.

Accelerated vertebral bone loss in relation to the menopause: a cross-sectional study on lumbar bone density in 286 women of 46 to 55 years of age.

F. V. Van Ginkel, J. C. Netelenbos, P. van der Stelt, 1988, Bone and mineral.

Perimenopausal bone mass and risk factors.

P. Lips, F. V. Van Ginkel, J. C. Netelenbos, 1989, Bone and mineral.

Pubertal Maturation Characteristics and the Rate of Bone Mass Development Longitudinally Toward Menarche

H. Delemarre-van de Waal, M. V. van’t Hof, J. C. Netelenbos, 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Postmenopausal hormone replacement, risk estimators for coronary artery disease and cardiovascular protection.

C. Stehouwer, P. Kenemans, J. C. Netelenbos, 1999, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

Meningioma in untreated congenital adrenal hyperplasia: a relationship?

M. Blankenstein, A. Heijboer, J. C. Netelenbos, 2009, Journal of Neuro-Oncology.

Calcium supplementation reduces vertebral bone loss in perimenopausal women: a controlled trial in 248 women between 46 and 55 years of age.

P. Lips, F. V. Van Ginkel, O. Leeuwenkamp, 1991, The Journal of clinical endocrinology and metabolism.

Neither long-term treatment with raloxifene nor hormone replacement therapy modulate cardiac function in healthy postmenopausal women: two randomized, placebo-controlled, 2-year studies.

O. Kamp, P. Kenemans, T. Vogelvang, 2002, American journal of obstetrics and gynecology.

A 2-year, randomized, comparative, placebo-controlled study on the effects of raloxifene on lipoprotein(a) and homocysteine.

W. M. van Baal, P. Kenemans, T. Vogelvang, 2002, Maturitas.

Raloxifene reduces impedance to flow within the uterine artery in early postmenopausal women: a 2-year randomized, placebo-controlled, comparative study.

W. M. van Baal, P. Kenemans, J. C. Netelenbos, 2001, American journal of obstetrics and gynecology.

Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation

P. Lips, Lex van de Langerijt, D. Hommes, 2013, Gut.

Collaboration Around Rare Bone Diseases Leads to the Unique Organizational Incentive of the Amsterdam Bone Center

W. Lems, G. Pals, A. Lammertsma, 2020, Frontiers in Endocrinology.

Raloxifene and hormone replacement therapy increase arachidonic acid and docosahexaenoic acid levels in postmenopausal women.

E. Giltay, E. J. Duschek, M. Katan, 2004, The Journal of endocrinology.

Selective determination of hydroxyproline in urine by high-performance liquid chromatography using precolumn derivatization.

J. C. Netelenbos, T. Teerlink, P. Tavenier, 1989, Clinica chimica acta; international journal of clinical chemistry.

Daily Oral Pamidronate in Women and Men With Osteoporosis: A 3‐Year Randomized Placebo‐Controlled Clinical Trial With a 2‐Year Open Extension

A. Zwinderman, P. Lips, E. McCloskey, 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women.

J. C. Netelenbos, J. Roos, R. Evertz, 2002, Bone.

Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW).

A. LaCroix, C. Cooper, S. Boonen, 2012, Bone.

Effects of administration of 17β‐oestradiol on serum leptin levels in healthy postmenopausal women

J. C. Netelenbos, J. Elbers, C. Popp‐Snijders, 1999 .

Radiologic morphometry in patients with femoral neck fractures and elderly control subjects. Comparison with histomorphometric parameters.

F. V. Van Ginkel, J. C. Netelenbos, P. Lips, 1984, Clinical orthopaedics and related research.

Volumetric measurements of bone mineral density of the lumbar spine: comparison of three geometrical approximations using dual-energy X-ray absorptiometry (DXA)

R. Manoliu, A. van Lingen, J. C. Netelenbos, 1998, Nuclear medicine communications.

Obesity, Health-Care Utilization, and Health-Related Quality of Life After Fracture in Postmenopausal Women: Global Longitudinal Study of Osteoporosis in Women (GLOW)

A. LaCroix, C. Cooper, S. Silverman, 2013, Calcified Tissue International.

Risk Factors for Treatment Failure With Antiosteoporosis Medication: The Global Longitudinal Study of Osteoporosis in Women (GLOW)

A. LaCroix, C. Cooper, S. Silverman, 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Histomorphometric analysis reveals reduced bone mass and bone formation in patients with quiescent Crohn's disease.

P. Lips, D. Hommes, C. J. van der Woude, 2011, Gastroenterology.

Sporadic hyperphosphatasia syndrome featuring periostitis and accelerated skeletal turnover without receptor activator of nuclear factor-kappaB, osteoprotegerin, or sequestosome-1 gene defects.

J. C. Netelenbos, S. Mumm, M. Whyte, 2007, The Journal of clinical endocrinology and metabolism.

The effect of cross‐gender hormonal treatment on bone metabolism in male‐to‐female transsexuals

J. C. Netelenbos, H. Asscheman, L. Gooren, 1989 .

Impact of prevalent fractures on quality of life: baseline results from the global longitudinal study of osteoporosis in women.

A. LaCroix, C. Cooper, S. Boonen, 2010, Mayo Clinic proceedings.

Spine radiographs to improve the identification of women at high risk for fractures

P. Geusens, W. Lems, J. C. Netelenbos, 2009, Osteoporosis International.

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2014): Oral Communication Abstracts

A. LaCroix, D. Hosmer, C. Cooper, 2014, Osteoporosis International.

Short-term effects of Org OD 14 and 17β-oestradiol on bone and lipid metabolism in early postmenopausal women

O. Leeuwenkamp, J. C. Netelenbos, P. Lips, 1991 .

Seasonal variation in serum concentrations of parathyroid hormone in elderly people.

F. V. Van Ginkel, J. C. Netelenbos, M. Jongen, 1983, The Journal of clinical endocrinology and metabolism.

Estrogen replacement therapy continuously combined with four different dosages of dydrogesterone: effect on calcium and lipid metabolism.

P. Kenemans, J. C. Netelenbos, G. Voetberg, 1994, The Journal of clinical endocrinology and metabolism.

Long‐term effect of calcium supplementation on bone loss in perimenopausal women

F. V. Van Ginkel, J. C. Netelenbos, P. van der Stelt, 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Increase in Fracture Risk Following Unintentional Weight Loss in Postmenopausal Women: The Global Longitudinal Study of Osteoporosis in Women

A. LaCroix, C. Cooper, A. Díez-Pérez, 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

The effect of trauma on serum concentrations of vitamin D metabolites in patients with hip fracture.

F. V. Van Ginkel, R. Bouillon, J. C. Netelenbos, 1985, Bone.

Lower mobility and markers of bone resorption in the elderly.

F. V. Van Ginkel, J. C. Netelenbos, P. Lips, 1990, Bone and mineral.

Regional Differences in Incident Prefrailty and Frailty

A. LaCroix, C. Cooper, A. Díez-Pérez, 2017 .

Estrogen Regulation of Intestinal Calcium Absorption in the Intact and Ovariectomized Adult Rat

J. C. Netelenbos, W. van der Vijgh, R. Barto, 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Oral 17&bgr;-estradiol (1 mg) continuously combined with dydrogesterone improves the serum lipid profile of postmenopausal women

O. Chevallier, J. C. Netelenbos, B. Pornel, 2002, Menopause.

Simultaneous determination of 25-hydroxyvitamin D, 24,25-dihydroxyvitamin D, and 1,25-dihydroxyvitamin D in plasma or serum.

J. C. Netelenbos, M. Jongen, P. Lips, 1981, Clinical chemistry.

Oral 17β-Estradiol Continuously Combined with Dydrogesterone Lowers Serum Lipoprotein(a) Concentrations in Healthy Postmenopausal Women1

P. Kenemans, J. C. Netelenbos, G. Kamp, 1997 .

International management of bone health in glucocorticoid-exposed individuals in the observational GLOW study

C. Cooper, S. Silverman, A. Díez-Pérez, 2014, Osteoporosis International.

Growth hormone (replacement) therapy in adults: bone and calcium metabolism.

J. C. Netelenbos, E. van der Veen, J. Netelenbos, 1990, Hormone research.

Fracture prevention by screening for high fracture risk: a systematic review and meta-analysis

H. E. van der Horst, J. C. Netelenbos, P. Elders, 2019, Osteoporosis International.

Fibrodysplasia Ossificans Progressiva: What Have We Achieved and Where Are We Now? Follow-up to the 2015 Lorentz Workshop

R. Ravazzolo, E. Hsiao, G. Pals, 2021, Frontiers in Endocrinology.

Topically applied low-dose calcitriol has no calciotropic effect in patients with stable plaque psoriasis.

J. C. Netelenbos, C. Nieboer, W. van der Vijgh, 1994, Journal of the American Academy of Dermatology.

An international comparison of vitamin D metabolite measurements.

F. V. Van Ginkel, J. C. Netelenbos, M. Jongen, 1984, Clinical chemistry.

Oestrogen has no short‐term effect on intestinal strontium absorption in healthy postmenopausal women

J. C. Netelenbos, W. van der Vijgh, R. Barto, 1999, Clinical endocrinology.

Human Pharmacokinetics of Orally Administered (24 R)-Hydroxycalcidiol

O. Leeuwenkamp, J. C. Netelenbos, P. Lips, 1993, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

Clinical implications of estimation of intact parathyroid hormone (PTH) versus total immunoreactive PTH in normal subjects and hyperparathyroid patients.

J. C. Netelenbos, P. Lips, C. Lips, 1986, The Journal of clinical endocrinology and metabolism.

Estrogen enhances growth hormone receptor expression and growth hormone action in rat osteosarcoma cells and human osteoblast-like cells.

C. Ohlsson, J. C. Netelenbos, O. Isaksson, 1997, The Journal of endocrinology.

Analysis for 1,25-dihydroxyvitamin D in human plasma, after a liquid-chromatographic purification procedure, with a modified competitive protein-binding assay.

J. C. Netelenbos, M. Jongen, W. van der Vijgh, 1981, Clinical chemistry.

Vitamin D status in urinary calcium stone formation.

F. V. Van Ginkel, J. C. Netelenbos, M. Jongen, 1985, Archives of internal medicine.

The effect of cross‐gender hormonal treatment on bone metabolism in male‐to‐female transsexuals

P. Lips, L. Gooren, J. C. Netelenbos, 1989, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Bone metabolism markers and bone mass in healthy pubertal boys and girls

H. Delemarre-van de Waal, J. C. Netelenbos, J. Roos, 2002, Clinical endocrinology.

One-hour test for estimating intestinal absorption of calcium by using stable strontium as a marker.

J. C. Netelenbos, P. Lips, W. van der Vijgh, 1994, Clinical chemistry.

Oestrogen replacement therapy lowers plasma levels of asymmetrical dimethylarginine in healthy postmenopausal women.

C. Stehouwer, J. C. Netelenbos, T. Teerlink, 2003, Clinical science.

Dexamethasone increases and serum decreases growth hormone receptor binding to UMR-106.01 rat osteosarcoma cells.

J. Salles, J. C. Netelenbos, C. P. de Vries, 1994, Endocrinology.

Growth hormone binds to a single high affinity receptor site on mouse osteoblasts: modulation by retinoic acid and cell differentiation.

C. Ohlsson, J. Salles, J. C. Netelenbos, 1996, Journal of Endocrinology.

Insulin-like growth factor binding proteins-2 and -3 stimulate growth hormone receptor binding and mitogenesis in rat osteosarcoma cells.

C. Ohlsson, J. Salles, J. C. Netelenbos, 1995, Endocrinology.

Measurement of vitamin D metabolites in anephric subjects.

J. C. Netelenbos, M. Jongen, P. Lips, 1984, Nephron.

Raloxifene reduces procarboxypeptidase U, an antifibrinolytic marker. A 2-year randomized, placebo-controlled study in healthy early postmenopausal women

P. Kenemans, T. Vogelvang, J. C. Netelenbos, 2004, Menopause.

Stimulation and suppression of intact parathyroid hormone (PTH1–84) in normal subjects and hyperparathyroid patients

J. C. Netelenbos, P. Lips, W. Hackeng, 1991, Clinical endocrinology.

Continuously combined hormone replacement therapy and bone turnover: the influence of dydrogesterone dose, smoking and initial degree of bone turnover.

P. Kenemans, J. C. Netelenbos, C. Popp‐Snijders, 1997, Maturitas.

Growth hormone receptor activity is stimulated by insulin-like growth factor binding protein 5 in rat osteosarcoma cells.

C. Ohlsson, J. C. Netelenbos, D. Andress, 1996, Growth regulation.

Bone mineral content of transilial biopsies in patients with hip fracture.

E. Hogervorst, J. C. Netelenbos, P. Lips, 1985, Bone.

Pharmacokinetics of 24,25-Dihydroxyvitamin D3 in Humans

J. C. Netelenbos, M. Jongen, P. Lips, 1989, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

Effect of estrogen on intestinal strontium absorption in postmenopausal women.

J. C. Netelenbos, W. van der Vijgh, R. Barto, 2000, Maturitas.

Calcium Supplementation Reduces Vertebral Bone Loss in Perimenopausal Women: A Controlled Trial in 248 Women between 46 and 55 Years of Age

O. Leeuwenkamp, J. C. Netelenbos, P. Lips, 1992 .

Improvements in the Simultaneous Determination of Calcidiol and Calcitriol in Human Serum or Plasma

J. C. Netelenbos, M. Jongen, P. Lips, 1988, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie.

Interlaboratory Variation of Vitamin D Metabolite Measurements

R. Bosch, T. Visser, J. C. Netelenbos, 1982, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie.

A commentary on steroid treatment in multiple sclerosis.

C. Polman, G. Teule, J. C. Netelenbos, 1991, Archives of neurology.

Strontium as a marker for intestinal calcium absorption: the stimulatory effect of calcitriol.

J. C. Netelenbos, W. van der Vijgh, R. Barto, 2000, Clinical chemistry.

Effects of administration of 17beta-oestradiol on serum leptin levels in healthy postmenopausal women.

J. C. Netelenbos, J. Elbers, C. Popp‐Snijders, 1999, Clinical endocrinology.

[Vitamin D deficiency and hip fracture].

J. C. Netelenbos, P. Lips, J. Netelenbos, 1985, Tijdschrift voor gerontologie en geriatrie.

Preclinical screening of the applicability of strontium as a marker for intestinal calcium absorption.

J. C. Netelenbos, W. van der Vijgh, R. Barto, 1997, The American journal of physiology.

Intestinal absorption of strontium chloride in healthy volunteers: pharmacokinetics and reproducibility.

J. C. Netelenbos, W. van der Vijgh, R. Barto, 2003, British journal of clinical pharmacology.

Sensitive method for analysis of strontium in human and animal plasma by graphite furnace atomic absorption spectrophotometry.

J. C. Netelenbos, W. van der Vijgh, R. Barto, 1995, Clinical chemistry.

Quantification of strontium in plasma and urine with flameless atomic absorption spectrometry.

O. Leeuwenkamp, J. C. Netelenbos, P. Lips, 1989, Clinical chemistry.

Bone Histomorphometric Evaluation of Pamidronate Treatment in Clinically Manifest Osteoporosis

P. Lips, J. C. Netelenbos, S. Papapoulos, 1999, Osteoporosis International.

Oxybutynin: dry days for patients with hyperhidrosis.

R. S. V. STRACK VAN SCHIJNDEL, J. C. Netelenbos, G. S. Mijnhout, 2006, The Netherlands journal of medicine.

lmmunoadsorptionassayfor bone alkaline phosphatasecomparedwith wheat germ agglutininprecipitationassayin serum from (pre)pubertalgirls

J. C. Netelenbos, A. A. Bouman, J. Nijhof, 1996 .

An analysis of bone structure in patients with hip fracture.

J C Netelenbos, J. C. Netelenbos, P. Lips, 1987, Bone and mineral.

Bone marrow and bone remodeling.

F. V. Van Ginkel, J. C. Netelenbos, P. Lips, 1985, Bone.

Microarchitecture of Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva: An HR-pQCT Case Series

B. van Rietbergen, J. C. Netelenbos, J. V. D. van den Bergh, 2021, Frontiers in Cell and Developmental Biology.

Diagnostic Value of Magnetic Resonance Imaging in Fibrodysplasia Ossificans Progressiva

G. Pals, A. Lammertsma, M. Yaqub, 2020, JBMR plus.

Radiotherapy in Fibrodysplasia Ossificans Progressiva: A Case Report and Systematic Review of the Literature

A. Lammertsma, L. Schoonmade, M. Dahele, 2020, Frontiers in Endocrinology.

Flare‐Up After Maxillofacial Surgery in a Patient With Fibrodysplasia Ossificans Progressiva: An [18F]‐NaF PET/CT Study and a Systematic Review

G. Pals, A. Lammertsma, D. Micha, 2017, JBMR plus.

An increased rate of falling leads to a rise in fracture risk in postmenopausal women with self-reported osteoarthritis: a prospective multinational cohort study (GLOW)

C. Cooper, S. Boonen, A. Díez-Pérez, 2012, Annals of the rheumatic diseases.

Bone histomorphometry and serum concentrations of intact parathyroid hormone (PTH(1-84)) in patients with primary hyperparathyroidism.

J. C. Netelenbos, P. Lips, W. Hackeng, 1993, Bone and mineral.

Clinical Utility Gene Card for: Fibrodysplasia ossificans progressiva

G. Pals, A. Bullock, F. Ventura, 2015, European Journal of Human Genetics.

Camurati–Engelmann disease (progressive diaphyseal dysplasia) in a Moroccan family

K. Janssens, W. Hul, J. Veenstra, 2005, Osteoporosis International.

When, Where and How Osteoporosis-Associated Fractures Occur: An Analysis from the Global Longitudinal Study of Osteoporosis in Women (GLOW)

Nelson B. Watts, Steven Boonen, Jonathan D. Adachi, 2013, PloS one.

Previous fractures at multiple sites increase the risk for subsequent fractures: The global longitudinal study of osteoporosis in women

A. LaCroix, C. Cooper, S. Boonen, 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Hyperparathyroidism after radioactive iodine therapy.

J. C. Netelenbos, P. Lips, 1981, Archives of internal medicine.

Effects of short-term low-dose heparin administration on biochemical parameters of bone turnover.

P. Lips, J. C. Netelenbos, P. Huijgens, 1993, Bone and mineral.

Growth hormone induces tyrosine phosphorylation of annexin I in rat osteosarcoma cells.

J. Salles, J. C. Netelenbos, M. Slootweg, 1996, Endocrinology.

Effect of raloxifene and hormone therapy on serum markers of brain and whole-body cholesterol metabolism in postmenopausal women.

T. Vogelvang, J. C. Netelenbos, D. Lütjohann, 2005, Maturitas.

Adherence and profile of non-persistence in patients treated for osteoporosis—a large-scale, long-term retrospective study in The Netherlands

P. Geusens, J. C. Netelenbos, P. Geusens, 2010, Osteoporosis International.

The effect of vitamin D supplementation on vitamin D status and parathyroid function in elderly subjects.

P. Delmas, F. V. Van Ginkel, J. C. Netelenbos, 1988, The Journal of clinical endocrinology and metabolism.

Self-perception of fracture risk: what can it tell us?

A. LaCroix, C. Cooper, S. Silverman, 2017, Osteoporosis International.

Intestinal strontium absorption: from bioavailability to validation of a simple test representative for intestinal calcium absorption.

J. C. Netelenbos, W. van der Vijgh, R. Barto, 1995, Clinical chemistry.

Generation of Fibrodysplasia ossificans progressiva and control integration free iPSC lines from periodontal ligament fibroblasts.

M. Goumans, J. C. Netelenbos, D. de Jong, 2019, Stem cell research.

The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design

A. LaCroix, C. Cooper, S. Silverman, 2009, Osteoporosis International.

The relation between periodontitis and systemic bone mass in women between 46 and 55 years of age.

J. C. Netelenbos, P. van der Stelt, L. Habets, 1992, Journal of clinical periodontology.

The Effect of a Screening and Treatment Program for the Prevention of Fractures in Older Women: A Randomized Pragmatic Trial

F. Rutters, A. A. van der Heijden, M. Heymans, 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Design of the SALT Osteoporosis Study: a randomised pragmatic trial, to study a primary care screening and treatment program for the prevention of fractures in women aged 65 years or older

F. Rutters, P. Lips, A. A. van der Heijden, 2017, BMC Musculoskeletal Disorders.

Empirically based composite fracture prediction model from the Global Longitudinal Study of Osteoporosis in Postmenopausal Women (GLOW).

A. LaCroix, D. Hosmer, C. Cooper, 2014, The Journal of clinical endocrinology and metabolism.

Predicting fractures in an international cohort using risk factor algorithms without BMD

A. LaCroix, D. Hosmer, C. Cooper, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Disease-specific perception of fracture risk and incident fracture rates: GLOW cohort study

A. LaCroix, C. Cooper, S. Silverman, 2013, Osteoporosis International.

Histomorphometric profile and vitamin D status in patients with femoral neck fracture.

F. V. Van Ginkel, J. C. Netelenbos, M. Jongen, 1982, Metabolic bone disease & related research.

Determinants of vitamin D status in patients with hip fracture and in elderly control subjects.

P. Lips, F. V. Van Ginkel, J. C. Netelenbos, 1987, The American journal of clinical nutrition.

Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW)

A. LaCroix, C. Cooper, S. Silverman, 2010, Osteoporosis International.

Non-hip, non-spine fractures drive healthcare utilization following a fracture: the Global Longitudinal Study of Osteoporosis in Women (GLOW)

A. LaCroix, C. Cooper, S. Silverman, 2012, Osteoporosis International.

Effect of a single infusion of aminohydroxypropylidene on calcium and bone metabolism in healthy volunteers monitored during 2 months.

F. V. Van Ginkel, O. Leeuwenkamp, J. C. Netelenbos, 1991, The Journal of clinical endocrinology and metabolism.

Intra-Individual Variation in Bone Resorption Markers in Urine

J. C. Netelenbos, P. Lips, C. Popp‐Snijders, 1996, Annals of clinical biochemistry.

Intranasal calcitonin suppresses increased bone resorption during short‐term immobilization: A double‐blind study of the effects of intranasal calcitonin on biochemical parameters of bone turnover

G. Kwakkel, J. Nauta, P. Lips, 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Burden of non-hip, non-vertebral fractures on quality of life in postmenopausal women

A. LaCroix, C. Cooper, S. Silverman, 2012, Osteoporosis International.

Regional and age-related variations in the proportions of hip fractures and major fractures among postmenopausal women: the Global Longitudinal Study of Osteoporosis in Women

A. LaCroix, C. Cooper, S. Silverman, 2012, Osteoporosis International.

FRACTURE PATTERNS WITH SELECTIVE SEROTONIN RECEPTOR INHIBITOR, PROTON PUMP INHIBITOR AND GLUCOCORTICOIDS USE IN GLOW

A. LaCroix, C. Cooper, S. Silverman, 2014 .

Raloxifene affects brain activation patterns in postmenopausal women during visual encoding.

S. Rombouts, P. Scheltens, F. Barkhof, 2001, The Journal of clinical endocrinology and metabolism.

[The Dutch Institute for Health Care Improvement (CBO) guideline for the diagnosis and treatment of aspecific acute and chronic low back complaints].

W. Lems, J. C. Netelenbos, 2004, Nederlands tijdschrift voor geneeskunde.

Biochemical parameters of bone turnover during ten days of bed rest and subsequent mobilization.

J. Nauta, P. Lips, G. Hazenberg, 1991, Bone and mineral.

Oral 17 beta-estradiol continuously combined with dydrogesterone lowers serum lipoprotein(a) concentrations in healthy postmenopausal women.

P. Kenemans, J. C. Netelenbos, G. V. van Kamp, 1997, Journal of Clinical Endocrinology and Metabolism.

[Teriparatide: an anabolic drug for the treatment of patients with osteoporosis].

W. Lems, J. C. Netelenbos, N. Hamdy, 2006, Nederlands tijdschrift voor geneeskunde.